Tarsus Pharmaceuticals Announces Agreement To Acquire Alkeus For $450M Upfront In Cash And Stock, Up To $350M In Milestones, Adding Phase 3 Stargardt Disease Therapy

Loading news article.

Tarsus Pharmaceuticals Announces Agreement To Acquire Alkeus For $450M Upfront In Cash And Stock, Up To $350M In Milestones, Adding Phase 3 Stargardt Disease Therapy | WAPE

Tarsus Pharmaceuticals Announces Agreement To Acquire Alkeus For $450M Upfront In Cash And Stock, Up To $350M In Milestones, Adding Phase 3 Stargardt Disease Therapy

Article summary

Related companies

Comments —